<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00171366</url>
  </required_header>
  <id_info>
    <org_study_id>CCIB002H2304</org_study_id>
    <nct_id>NCT00171366</nct_id>
  </id_info>
  <brief_title>A Study Comparing the Response of Patients With Hypertension to Amlodipine or Amlodipine Plus Benazepril.</brief_title>
  <official_title>A Multicenter, Group Study to Evaluate the Safety and Efficacy of Amlodipine and Benazepril Administered in Combination Compared to Amlodipine Monotherapy in Hypertensive Patients Not Adequately Controlled With Amlodipine Alone</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Novartis</source>
  <brief_summary>
    <textblock>
      Comparison of the safety and efficacy of the combination of amlodipine/Benazepril to
      amlodipine monotherapy in patients with non-essential hypertension, not controlled on
      amlodipine alone.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2004</start_date>
  <completion_date type="Actual">July 2005</completion_date>
  <primary_completion_date type="Actual">July 2005</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in mean sitting diastolic blood pressure at week 6</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in mean sitting systolic blood pressure at week 6</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from week 2 in mean sitting diastolic and systolic blood pressure at week 6</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Diastolic response rate at week 6. Patients were considered responders if they had a mean sitting diastolic blood pressure of &lt; 90 mmHg or a &gt;= 10 mm Hg decrease compared to baseline.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24 hour diastolic and systolic blood pressure at week 6</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in 24 hour diastolic and systolic blood pressure at peak which is defined as the lowest hourly blood pressure mean and the average of the hourly means from 4 to 6 hours post dose at week 6</measure>
  </secondary_outcome>
  <enrollment type="Actual">1422</enrollment>
  <condition>Hypertension</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>amlodipine/benazepril</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Outpatients 18 years of age or older.

          -  Male or female patients are eligible. Female patients must be either post-menopausal
             for one year or surgically sterile, or using effective, contraceptive methods such as
             barrier method with spermicide, or an intrauterine device.

          -  Patients with essential hypertension as measured by a validated device

        Exclusion Criteria:

          -  Severe hypertension (DBP &gt; 115 mmHg diastolic and/or SBP &gt; 180 mmHg systolic).

        Other protocol-defined exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Novartis Pharmaceuticals</name>
      <address>
        <city>E. Hanover</city>
        <state>New Jersey</state>
        <zip>07936</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2005</study_first_submitted>
  <study_first_submitted_qc>September 12, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 15, 2005</study_first_posted>
  <last_update_submitted>April 5, 2016</last_update_submitted>
  <last_update_submitted_qc>April 5, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 6, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>amlodipine</keyword>
  <keyword>benazepril</keyword>
  <keyword>hypertension</keyword>
  <keyword>diastolic</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Benazepril</mesh_term>
    <mesh_term>Amlodipine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

